Stoke Therapeutics · 3 hours ago
Principal Scientist, Oligonucleotide Chemistry
Bedford, Massachusetts, United States
Full-time
Onsite
Lead/Staff
$169K/yr - $191K/yr
8+ years expStoke Therapeutics is a biotechnology company focused on restoring protein expression through RNA medicine. They are seeking a Principal Scientist in Oligonucleotide Chemistry to lead the synthesis of bioactive oligonucleotides for drug discovery programs, contributing technical knowledge and managing projects with strict timelines.
BiotechnologyHealth CarePharmaceuticalTherapeutics
Responsibilities
Independently design and implement scientific and synthesis strategies relating to the research and development of antisense and other synthetic oligonucleotide therapeutics
Contribute to multiple projects and provide key technical knowledge to the project team
Plan and execute solid-phase oligonucleotide synthesis for SAR campaigns on several projects
Participate in the identification, development, validation and implementation of both current and next-generation technologies to enable proprietary ASO therapeutic development including purchase and installation of hardware and software supporting synthesis, purification, and characterization of oligonucleotides
Demonstrate working knowledge of conjugation chemistry and techniques aimed at producing novel conjugates
Demonstrates understanding of the chemistry of nucleosides, nucleotides, and oligonucleotides as applied to antisense and other oligonucleotide technologies
Stay current with scientific literature and understanding of the state of the art in oligonucleotide chemistry, purification, and screening strategies
Work with both internal chemistry team and external CRO’s to generate innovative solutions to synthetic and drug design challenges within the context of oligonucleotide drug discovery projects
Authors reports and manuscripts. May contribute to patent filings and/or regulatory filing
Qualification
Required
PhD in Oligonucleotide Chemistry and relevant experience in a drug discovery environment with at least 8 years of oligonucleotide synthesis experience in a drug discovery environment, Master's degree with 12+ years of experience or Bachelor's degree with 18+ years of experience
Strong practical knowledge of design, synthesis, and purification of synthetic oligonucleotides
Excellent project/time management, and problem-solving skills
Excellent written and verbal communication skills, including making effective and compelling presentations in both large and small groups and communicating complex scientific and nonscientific issues to program teams
Strong people skills and the ability to thrive in a team and goal driven environment
Experience designing, synthesizing and purifying oligonucleotides to support research and scale up studies
Proven track record of scientific contributions in oligonucleotide and conjugates research as evidenced by publications/presentations/patent applications and/or the identification of preclinical development candidates
Preferred
Experience in scale-up synthesis would be a plus
Benefits
Medical, dental and vision insurance
Life, long and short-term disability insurance
Paid parental leave
A 401K plan with company match
Unlimited vacation time
Tuition assistance
Participation in our Employee Stock Purchase Program (ESPP)
Company
Stoke Therapeutics
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.
51-200 employees
H1B Sponsorship
Stoke Therapeutics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (2)
2024 (1)
2023 (2)
2020 (2)
Funding
Current Stage
Public CompanyTotal Funding
$360.1MKey Investors
Apple Tree Partners
2024-03-27Post Ipo Equity· $125M
2020-11-24Post Ipo Equity· $105.1M
2019-06-19IPO
Leadership Team
Edward Kaye
CEO & Founder
Adrian Krainer
Co-founder & Director
Recent News
Company data provided by crunchbase